BIVI BioVie Inc.
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2b clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.…
Industry Peers
BiotechnologyKey Statistics
About BioVie (NASDAQ: BIVI)
›
BioVie (NASDAQ: BIVI) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 13 employees.
The shares were at 0.9098 USD on 19 November 2026, down 39.3% over 52 weeks. Its 52-week range is 0.8200 USD to 3.790 USD: the price is 76.0% below the high and 11.0% above the low.
Its market capitalisation is 9.76M USD.
BioVie reports return on equity of -214.9% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 7.48M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 5 February 2027.